X4 Pharmaceuticals, Inc. (XFOR) financial statements (2021 and earlier)

Company profile

Business Address 61 NORTH BEACON STREET
BOSTON, MA 02134
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments7912631
Cash and cash equivalents7912631
Restricted cash and investments0 0
Prepaid expense  1
Other undisclosed current assets433
Total current assets:8312935
Noncurrent Assets
Operating lease, right-of-use asset82
Property, plant and equipment100
Intangible assets, net (including goodwill)2727 
Goodwill2727 
Restricted cash and investments  1
Other noncurrent assets320
Total noncurrent assets:40311
TOTAL ASSETS:12316136
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1195
Accounts payable321
Accrued liabilities864
Debt 1 
Other undisclosed current liabilities1 1
Total current liabilities:1295
Noncurrent Liabilities
Long-term debt and lease obligation4228
Long-term debt, excluding current maturities 208
Operating lease, liability42
Liabilities, other than long-term debt000
Other liabilities000
Other undisclosed noncurrent liabilities3301
Total noncurrent liabilities:38229
Total liabilities:503114
Stockholders' equity
Stockholders' equity attributable to parent7312922
Common stock000
Additional paid in capital267261157
Accumulated other comprehensive income (loss)(0)(0)0
Accumulated deficit(194)(132)(135)
Total stockholders' equity:7312922
TOTAL LIABILITIES AND EQUITY:12316136

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Sublease income00
Gross profit:304
Operating expenses(63)(52)(49)
Other undisclosed operating loss (0) 
Operating loss:(60)(52)(46)
Nonoperating income (expense)(2)(1)3
Investment income, nonoperating011
Other nonoperating income (expense)11(0)
Interest and debt expense(0)(1)(1)
Other undisclosed income from continuing operations before equity method investments, income taxes011
Loss from continuing operations before income taxes:(62)(53)(43)
Income tax expense(0)  
Net loss attributable to parent:(62)(53)(43)
Preferred stock dividends and other adjustments (1) 
Net loss available to common stockholders, diluted:(62)(53)(43)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Net loss:(62)(53)(43)
Comprehensive loss:(62)(53)(43)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent (0)0
Comprehensive loss, net of tax, attributable to parent:(62)(53)(43)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: